Search

Displaying results 3111 - 3120 of 10000 in total
  1. Drug

    Aminocaproic acid

    go.drugbank.com/drugs/DB00513
    ApprovedInvestigational

    An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.

    Mixtures: Relief and Nature Toothpast E Jasmine MintInternational brands: E-Capro
  2. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … [L43917] Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineages BA.4 and BA.5.

    Categories: Complex Mixtures
  3. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

    Categories: Vasodilators Used in Cardiac Diseases
  4. Drug

    Naldemedine

    go.drugbank.com/drugs/DB11691
    ApprovedInvestigational

    Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. … Naldemedine is an opioid receptor antagonist [FDA Label].

  5. Drug

    Serelaxin

    go.drugbank.com/drugs/DB05794
    Investigational

    human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come

    Categories: Vasodilators Used in Cardiac Diseases
  6. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    [F94,A33105,A33106,A33108] It was approved by the FDA in February 2020 for the preventive treatment of migraine headaches in adults.[L12318]

  7. Drug

    Finafloxacin

    go.drugbank.com/drugs/DB09047
    ApprovedWithdrawn

    Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014. … Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.

  8. Drug

    Elosulfase alfa

    go.drugbank.com/drugs/DB09051
    ApprovedInvestigational

    Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. … The recommended dose is 2 mg per kg given intravenously over a minimum range of 3.5 to 4.5 hours, based on infusion volume, once every week.

    Synonyms: Recombinant human N-acetylgalactosamine-6-sulfatase, Recombinant human N-acetylgalactosamine-6-sulfatase (rhGALNS)
  9. Drug

    Transcrocetinate

    go.drugbank.com/drugs/DB05974
    Investigational

    Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Poloxamer 407

    go.drugbank.com/drugs/DB11252
    Investigational

    Poloxamer 407 is used as an emulsifying agent and solubilizing agent in cosmetic and personal products such as contact lens cleaning solutions. … It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature.

    Categories: Compounds used in a research, industrial, or household setting